OverviewChartNewsTraderScreen

Foghorn Therapeutics/  US3441741077  /

IEX
05/06/2024  21:59:05 Chg. +0.52 Volume Bid- Ask- High Low
6.19USD +9.17% 3,179
Turnover: 18,896.42		 -Bid Size: - -Ask Size: - 6.26 5.65
GlobeNewswire 28/05 Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
GlobeNewswire 24/05 Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO)...
GlobeNewswire 23/05 Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance...
GlobeNewswire 20/05 Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire 06/05 Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
GlobeNewswire 16/04 Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Fi...
GlobeNewswire 09/04 Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibit...
GlobeNewswire 05/04 Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
GlobeNewswire 26/03 Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Con...
GlobeNewswire 07/03 Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
GlobeNewswire 05/03 Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advance...
GlobeNewswire 28/02 Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
GlobeNewswire 15/02 OnKure Announces the Appointment of Samuel Agresta, M.D., as Chief Medical Officer
GlobeNewswire 08/02 Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
GlobeNewswire 08/01 Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategi...
GlobeNewswire 05/01 Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
GlobeNewswire 03/01 Foghorn Therapeutics Announces CFO Departure
GlobeNewswire 01/12/2023 Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibit...
GlobeNewswire 02/11/2023 Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
GlobeNewswire 24/10/2023 Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 an...
GlobeNewswire 13/10/2023 Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melan...
GlobeNewswire 04/10/2023 Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Div...
GlobeNewswire 05/09/2023 Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire 31/08/2023 Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relap...
GlobeNewswire 11/03/2022 Foghorn Therapeutics to Participate at the 2022 Guggenheim Targeted Protein Degradation Day